Andrea K Viecelli1, Wai H Lim, Petra Macaskill, Jeremy R Chapman, Jonathan C Craig, Philip Clayton, Solomon Cohney, Robert Carroll, Germaine Wong. 1. 1 Department of Renal Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia. 2 ANZDATA Registry, Royal Adelaide Hospital, Adelaide, South Australia, Australia. 3 School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia. 4 Sydney School of Public Health, University of Sydney, New South Wales, Australia. 5 Centre for Kidney Research, The Children's Hospital at Westmead, New South Wales, Australia. 6 Department of Nephrology, Western Hospital, University of Melbourne, Victoria, Australia. 7 Northwestern Academic Centre, University of Melbourne, Victoria, Australia. 8 Department of Nephrology, Central Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, South Australia, Australia. 9 Centre for Transplant and Renal Research, Westmead Hospital, New South Wales, Australia.
Abstract
BACKGROUND: For dialysis patients with a cancer history, a period of surveillance is generally recommended before listing for transplantation. However, the outcomes of patients with cancer recurrence and/or a second primary cancer after transplantation are unknown. AIM: To determine the prognosis of kidney transplant recipients who developed cancer after transplantation and whether this varied with cancer types (first cancer, recurrence, second primary cancer). METHODS: Using data from the Australian and New Zealand Dialysis and Transplant Registry, we compared the cancer-specific and all-cause mortality among recipients with different cancer types using adjusted Cox proportional hazard models. RESULTS: Of the 21,415 recipients transplanted between 1965 and 2012, 3% (651 of 21,415) had a previous cancer history. A total of 2840 (13%) recipients developed cancer after the first transplant, of whom 2760 (97.2%) developed a first cancer, 23 (0.8%) experienced cancer recurrence, and 57 (2%) developed a second primary cancer. There were no significant differences in the risks of cancer-specific and all-cause mortality between recipients who developed their first cancer after transplant, those with cancer recurrence (adjusted hazard ratios [aHRs], 0.79; 95% confidence interval [95% CI], 0.38-1.67; P = 0.54 and aHRs, 0.86; 95% CI, 0.45-1.66; P = 0.66, respectively) and recipients who developed a second primary cancer after transplantation (aHRs, 1.01; 95%CI, 0.63-1.62; P = 0.95 and aHRs, 1.16; 95% CI, 0.79-1.69; P = 0.45, respectively). CONCLUSION: Among patients with a previous history of malignancy, recurrent and second primary cancers are infrequent after renal transplantation. A history of previous malignancy does not have an additive effect on the cancer-specific and overall survival of kidney transplant recipients who develop cancer.
BACKGROUND: For dialysis patients with a cancer history, a period of surveillance is generally recommended before listing for transplantation. However, the outcomes of patients with cancer recurrence and/or a second primary cancer after transplantation are unknown. AIM: To determine the prognosis of kidney transplant recipients who developed cancer after transplantation and whether this varied with cancer types (first cancer, recurrence, second primary cancer). METHODS: Using data from the Australian and New Zealand Dialysis and Transplant Registry, we compared the cancer-specific and all-cause mortality among recipients with different cancer types using adjusted Cox proportional hazard models. RESULTS: Of the 21,415 recipients transplanted between 1965 and 2012, 3% (651 of 21,415) had a previous cancer history. A total of 2840 (13%) recipients developed cancer after the first transplant, of whom 2760 (97.2%) developed a first cancer, 23 (0.8%) experienced cancer recurrence, and 57 (2%) developed a second primary cancer. There were no significant differences in the risks of cancer-specific and all-cause mortality between recipients who developed their first cancer after transplant, those with cancer recurrence (adjusted hazard ratios [aHRs], 0.79; 95% confidence interval [95% CI], 0.38-1.67; P = 0.54 and aHRs, 0.86; 95% CI, 0.45-1.66; P = 0.66, respectively) and recipients who developed a second primary cancer after transplantation (aHRs, 1.01; 95%CI, 0.63-1.62; P = 0.95 and aHRs, 1.16; 95% CI, 0.79-1.69; P = 0.45, respectively). CONCLUSION: Among patients with a previous history of malignancy, recurrent and second primary cancers are infrequent after renal transplantation. A history of previous malignancy does not have an additive effect on the cancer-specific and overall survival of kidney transplant recipients who develop cancer.
Authors: Vikas R Dharnidharka; Abhijit S Naik; David Axelrod; Mark A Schnitzler; Huiling Xiao; Daniel C Brennan; Dorry L Segev; Henry Randall; Jiajing Chen; Bertram Kasiske; Krista L Lentine Journal: Transplantation Date: 2017-04 Impact factor: 4.939
Authors: Neval Ete Wareham; Caspar Da Cunha-Bang; Álvaro H Borges; Christina Ekenberg; Jan Gerstoft; Finn Gustafsson; Ditte Hansen; Carsten Heilmann; Marie Helleberg; Jens Hillingsø; Paul Suno Krohn; Isabelle Paula Lodding; Thomas Kromann Lund; Louise Lundgren; Amanda Mocroft; Michael Perch; Søren Lykke Petersen; Irma Petruskevicius; Allan Rasmussen; Kasper Rossing; Andreas A Rostved; Henrik Sengeløv; Vibeke Rømming Sørensen; Søren Schwartz Sørensen; Jens D Lundgren Journal: Medicine (Baltimore) Date: 2018-07 Impact factor: 1.889
Authors: Felix Becker; Anne-Sophie Mehdorn; Vasilios Getsopulos; Katharina Schütte-Nütgen; Stefan Reuter; Barbara Suwelack; Andreas Pascher; Jens G Brockmann; Ralf Bahde Journal: J Clin Med Date: 2021-05-27 Impact factor: 4.241